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Abstract
“Why didn’t they develop natural product drugs in a sustainable manner at the beginning of this century?”  In 2035, when about 10.0 billion
will inhabit Earth, will this be our legacy as the world contemplates the costs and availability of synthetic and gene-based products for
primary health care?  Acknowledging the recent history of the relationship between humankind and the Earth, it is essential that the health
care issues being left for our descendants be considered in terms of resources. For most people in the world, there are two vast health care
“gaps”, access to quality drugs and the development of drugs for major global and local diseases.  Consequently for all of these people,
plants, in their various forms, remain a primary source of health care.  In the developed countries, natural products derived from plants
assume a relatively minor role in health care, as prescription and over-the-counter products, even with the widespread use of
phytotherapeutical preparations.  Significantly, pharmaceutical companies have retrenched substantially in their disease areas of focus.
These research areas do not include the prevalent diseases of the middle- and lower-income countries, and important diseases of the
developed world, such as drug resistance. What then is the vision for natural product research to maintain the choices of drug discovery and
pharmaceutical development for future generations?  In this discussion some facets of how natural products must be involved globally, in
a sustainable manner, for improving health care will be examined within the framework of the new term “ecopharmacognosy”, which
invokes sustainability as the basis for research on biologically active natural products.  Access to the biome, the acquisition, analysis and
dissemination of plant knowledge, natural product structure diversification, biotechnology development, strategies for natural product drug
discovery, and aspects of multitarget therapy and synergy research will be discussed.  Options for the future will be presented which may
be significant as countries decide how to develop approaches to relieve their own disease burden, and the needs of their population for
improved access to medicinal agents.
Keywords: natural products, ecopharmacognosy, sustainable medicines, biotechnology, structure diversification, rain forest resources,
strategic implications
Introduction
In Lewis Carroll’s famous book “Alice in Wonderland;
Through the Looking Glass”, it is the Mad Hatter who has
the perspicacity to say to Alice “We are all mad here”.   In
many ways, given the recent and ongoing relationship
between humankind and the resources of the Earth, it is
we who are living in a world of madness, where resources
are squandered now, for instant benefit,  with little
consideration given for the resource needs of the
generations to follow.  And it we who, in spite of
numerous warnings and international meetings and
declarations, still cannot turn and say clearly that what we
are doing to the planet and its resources is indeed
“madness”, and must change if the human race is to
survive and thrive.  To borrow a phrase, “We are killing
the planet that heals us”.
The core madness in the scenario is this: a
dramatically increasing population, mostly in the middle-
and low-income countries, an alarming decrease in the
acreage of tropical rain forests, and an expanding
dependence on those resources and others for food,
shelter, and health care.  When, as we have seen, most of
the world relies on medicinal plants for their health care,
and up to 85% of those plants are harvested in a non-
renewable manner, it is clear to see that new strategies are
needed to assure access to medicinal agents in the future
(1-12).  The fourth factor, oil, remains a mysterious
unknown, an enigma with respect to long-term
accessibility.  Optimistic estimates of the current oil
resources, although accurate data are basically non-
available for financial and security reasons, would
suggest that they may be viable for the next 40-50 years.
However, population is increasing at a faster rate than oil
production. So what will be the status of the Earth’s
resources at that time, say in 2060, when renewable,
moderate cost, effective, alternative sources for synthetic
medicinal agents will be needed?
Enzymes, isolated or in intact systems, must be
deployed as an essential component of industrial drug
synthesis to reduce the dependency on non-renewable
resources.  The July, 2011 issue ofChemical Reviewswas
devoted to a series of eleven reviews of different types of
enzymes deployed for selective synthetic
transformations, several related to drug processes.  The
use of renewable, multifunctional enzyme systems which
can transpose a compound through to a final product with
minimal “chemical” reagent involvement may be an
important facet of the production of synthetic drugs
within ten years.  Considerations of the use of
inexpensive renewable reagents may also drive the
selection of both production processes and compounds
evaluated for their drug potential and eventual marketing.
Also to be developed further is the potential for the use of
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vegetables as chemical reagents for selected
enantioselective processes, where intact materials, not
isolated enzymes are utilized (13).  However, the need for
natural products, as quality traditional medicines, and as
sources for new medicinal agents will remain.  This brief
discussion is about some of those opportunities.
As natural product scientists, one of our obligations is
to initiate the discussion of how to investigate natural
resources for health care, and encourage others to see
different perspectives of the overall picture.  Our role is
also to examine, define, and articulate the niche of natural
products in the future of the population of Earth, and
particularly the anticipated role of natural products in
global health care.  It is also important that we, as the
content experts, have a scientific role in developing those
future plans.
The global population is now at 7.31 billion (April
2013), and is projected to rise to 10 billion by about 2035.
The causes and the implications for such a dramatic
population explosion are philosophical and religious,
which are considerations beyond the scope of this short
article, but upon which the fate of human existence hinges
(14, 15).   As one small, yet significant aspect of this huge
discussion, some of the many integrated aspects of natural
products in health care, we will review some possible
relationships between natural products and drug
discovery, and look one again at the important question:
“What is the future for natural products in global health?”
The author has written numerous articles on this area in
the past 25 years (1-6,16-24), with several of the more
recent articles focusing on two major issues, the concept
of medicines as a sustainable commodity (4-12), and
enhancing the quality control of traditional medicines in
global health (6-12,23-26).
On a daily basis, we often forget to acknowledge with
gratefulness the vast contributions that plants, their
extracts, and the various products derived from them,
make to human health and well-being: i) as foodstuffs, ii)
as flavoring agents and spices, iii) as perfumes and
cosmetics, and iv) as pharmaceutical and biological
agents.  These categories are not mutually exclusive, for
it is apparent that there is significant overlap between
foods, spices, cosmetics, and biological (medicinal)
agents.
It was estimated over 20 years ago that there are more
than 120 compounds from over 90 different plant
materials which are used on a global basis as prescription
products (27), and this number may well have risen since
then (28-32). Butler, for example, lists 34 natural product
based drugs introduced in the period 1998-2007 (31), and
Harvey lists 108 plant-derived compounds in various
development phases (32).  From a commercial
perspective, world-wide sales for plant-based
pharmaceutical agents in 2002 were estimated at US $30
billion (33).  In addition, there are also thousands of
products, compounds, plant extracts and plant materials,
some sanctioned as prescription products, others bought
over-the-counter, or in a market place, or through a local
medicine man or woman, which are recommended for
patient healing in various parts of the world.  For the vast
majority of the world, approximately 4.5 billion people,
these plant resources are their primary source of health
care (34).
There are many “gaps” in global health care, and per
capita government investment in health care in a
particular country (see Table 1 for some examples), is one
of the more staggering examples between the high-
income and the low-income countries.  That aspect of
health care concerned with medicinal agents for patient
treatment, pharmacy, is no exception.  For example, there
is a major regulatory “gap” between the prescription
products of the North and the products sold in a
marketplace as part of a traditional medicine system in a
middle- or low-income country.   One is highly regulated,
costing perhaps $1.3 billion to develop a product and
support continuing post-marketing surveillance (35).
Whereas the traditional medicine is almost completely
unregulated; in many countries, a plant material appears
in the street market directly from the field, just as it did
4000 years ago, and there are many variations of
regulation in this continuum of extremes.
The UN charter of 1948 clearly indicates that all
humans have the universal right to health care.  But what
is being done by the organizations of the UN to achieve
this? What does that universal right mean in terms of the
quality control of traditional medicines or for drug
discovery for global and local diseases? In this regard, we
must not be limited to thinking that drug discovery
involves only single compounds. In an era of systems
biology and network pharmacology, it is clear that the
period for thinking of drug discoveries as “magic bullets”
is long gone.
Table 1. Government Expenditures on Health per Capita (2009) in US
$.
Country US $
United States 7960
Norway 5383
Australia 3484
United Kingdom 3438
Republic of Korea 1879
Costa Rica 1155
Turkey 957
South Africa 930
Brazil 921
Iran 728
Peru 466
China 347
Vietnam 204
Philippines 133
India 124
Nigeria 136
Indonesia 100
Myanmar 36
Source:http://en.wikipedia.org/wiki/List_of_countries_by_total_health_ex
penditure _(PPP)_per_capita
In terms of plant-based health care, research is
drastically under-funded at the global and national levels
in terms of personnel, programs, products, and outcomes.
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The truth is that, as a moral and ethical issue, it is a
shameful international embarrassment, and requires a
complete reassessment of strategies, programs, and
outcomes from the very top of the UN through all of the
various agencies involved.  One group, Médecins Sans
Frontieres, justifiably, has called for a complete overall
of the whole drug discovery, development and access
system for the middle and lower-income areas of the
world given the history of drug innovation for the South
in the past thirty years (35).
Patients world-wide who acquire plant-based
products, either through prescription or as a street
medicine, in their various forms, are rightfully demanding
the same assurances of safety, efficacy, and consistency
as a patient taking a drug from a pharmaceutical
company. The “gap”, of course, is who is standing behind
those assurances?  Is it a government, a pharmaceutical
company, a traditional medicine provider?  If no-one is
making (or can make) those fundamental assurances,
based on science, what does that mean for the overall
health care of a nation?  As the wise man once said, if you
want the answer…. “follow the money.”
Although very basic, this is merely one of many health
care “gaps” that exist in the world at this time; another
gaggle of “gaps” concern the question of access.  In this
sense, the term is applied in four ways.  The first facet is
what are the prevalent diseases in a country for which
drugs are not available at all?  The second is what are the
diseases for which drugs are available globally, but which
are either too costly, or not available, locally?  The third
facet is what are the diseases for which there is resistance
to existing treatments?  The final facet of access relates to
the source of medicinal plant materials, and the long term
stability of a disappearing forest as a sustainable source
of medicinal agents.  These facets, individually or
collectively, can form the basis for rationalizing the need
for targeted new drug discovery programs, and for
placing that rationalization in a conservation and
sustainable development framework.  Access to health
care, and to medications in particular, is consequently a
global concern for all, with the exception of the very
wealthy.
Another of the medicine-related “gaps” in health care
relates to two questions: what are global health care
needs? And what is contemporary drug discovery in the
pharmaceutical industry targeting?  The “gap” between
these two responses is vast and expanding.  The global
health needs for over 1 billion people on Earth are
treatments for: malaria, HIV-AIDS, tuberculosis,
hepatitis C, diarrheal diseases, ascariasis, leishmaniasis,
schistosomiasis, trypanosomiasis, dengue fever, leprosy,
rabies, yaws, and necatoriasis.  Contemporary drug
discovery areas in the major pharmaceutical companies
have been winnowed to: antivirals, oncology,
metabolism, central nervous system ailments, and
inflammatory diseases (36). More recently, one major
company, AstraZeneca, has winnowed its research
portfolio to three areas: inflammatory and autoimmune
diseases, cardiovascular and metabolic diseases, and
oncology (37).  The logic behind these strategies is that
drug companies will make money when they produce
drugs which: i) will not encounter a resistance issue, as
occurs with antibiotics, ii) are taken on a chronic basis,
and iii) are palliative and not curative.  The global health
disease burden is not their concern.  It is really that
simple.
For individual countries, and for regional associations
of countries, such as ASEAN, many questions must be
asked in terms of the present and the future health care
needs.  There are limited precedents available, but recall
that it may take at least fifteen years to move from bench
to marketplace, if the strategy involves the development
of single agent drugs.  There are alternatives which also
should be considered, and which, depending on the
particular country situation, can serve either as interim
steps for enhancing health care, or as longer term
solutions.  Clearly though, not every country will have the
human capacity, the infrastructure, and the financial
resources to muster a drug discovery effort based on the
study of their natural resources. Even those countries who
do embark on that endeavor will need to clarify whether
all of the needed expertise is available in country, or
whether other regional or global resources need to be
accessed.
From a discovery perspective, countries have two
main natural resources at their disposal, their natural flora
and the indigenous knowledge, which may be within one
or several traditional systems of medicine.  These
resources offer a unique basis with which to develop a
strategy or a series of strategies for drug discovery.  In
this instance, the emphasis here is on a government
ministry, or most likely a group of ministries (science and
technology, health, education, agriculture, commerce),
and local (not the major) pharmaceutical companies,
coming together to serve as a catalyst to address this
aspect of health care.  Initiatives such as the discovery of
drugs or the enhancement of traditional medicines to meet
societal health needs cannot begin at the local level, but
must come “top down”, where government is both
“calling the shots” through establishing consultative
groups, and at the same time providing the highly targeted
resources for addressing long-term needs.  All parties,
government regulators and funding sources, botanical,
chemical and biological scientists, agronomists,
industrialists, and academics need to come together to
address these basic health care issues as a coordinated and
cooperative venture for the health of their population.
As we consider how to potentiate the available natural
resources for health care, it is also important to examine
the historical background to the interest in the tropical
forests.  It is not adequate to state that because plants have
yielded drugs in the past they will do so in the future.
Neither is it appropriate to conclude that because a
particular plant has a long history of use as a traditional
medicine that it should be approved as a drug.  Many
other considerations come into play, including the need
to place such assertions in science; the evidence-based
approach.
So what is the goal, and what are the strategies, of
exploring the rain forest for medicinal plants? Are there
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clear and rational reasons which can adequately justify
the investment?  If so, what is the nature (breadth, depth,
duration) of such an interest?  What if the discovery of
either an effective plant extract or an effective compound
is made?  What are the issues with respect to next stage
development, and how will further development, if
warranted, be supported financially?  Where and how
does the patenting of inventions impact the development
process?  What are the local implications in terms of
agricultural or infrastructure development?
Potentially, unraveling the human genome provides
an opportunity for the development of assays related to
numerous disease-related, new drug targets, once those
correlations have been determined.  Because of the
ethnomedical reputation of tens of thousands (perhaps 8-
10%) of terrestrial plants (4), once a prioritized
acquisition and screening schedule is achieved, very
specific opportunities for the selective evaluation of the
effectiveness and potential for further development of
traditional medicines may be achieved.
Strategically though, for the wider evaluation of plant
materials, and for more rapid and effective quality control
assessment of traditional medicines an important
paradigm needs to be reversed (9-12).  As a modality for
conducting preliminary screening programs for the
biological activity of plant extracts, bringing plant
materials from the collection site to the laboratory for
extraction and bioassay is an exceptionally inefficient
approach.  Depending where an “active” line is drawn,
but probably around the 2-4% level for most programs,
the extracts of 96-98% of the collected plant materials are
“inactive” in any particular biological assay.  While those
materials (and their parent plants) can be retained and
stored as an asset to the program, and subsequently
reassessed against new target assays in the future, the fact
remains that there is significant effort in collection,
drying, grinding, and extraction which is wasted.
Consequently, there is an urgent need for the
development of bioassay systems, preferably genome-
based, which can be performed, at collection site
locations, directly on plant extracts prepared in the field
using micro-extraction technology to remove unwanted
plant constituents. Further local plant collection would
then focus on those plant extracts which have a
demonstrated biological activity.  At the same time, the
frequent failure of plant extracts to reconfirm biological
activity on recollection will be reduced.
Who is potentially interested in exploring the rain
forest biodiversity for bioactive products?  Several types
of companies have a financial interest in plant-based
natural products and extracts.  In spite of the success of
plant-based pharmaceuticals, most of the large
pharmaceutical companies have terminated those aspects
of their drug discovery programs which are based on
plant-derived natural products.  The prime reasons for this
have been discussed elsewhere (1,3,4,9-12,20).  As
complex matrices, plant extracts provide a significant
challenge for the bioactivity-directed isolation of the
active principle(s).  In addition, this deconvolution step
may yield an undesirable known, rather than a novel,
active constituent. The second consideration is that the
recollection of a plant may be a time-consuming process,
require extensive (re-)negotiations related to access, and
may not be biologically active.  Yet another consideration
is the ability to provide an adequate supply of a compound
for additional biological evaluation in a timely and
reproducible manner.
For some biotechnology companies, the use of tissue
culture systems in order to examine the ability of cell-free
plant systems to produce metabolites which are not
present in field-grown plants has proved important, and
has provided an opportunity to study plant secondary
metabolic enzyme systems and obtain new compounds
for evaluation.  The botanical supplement companies are
finding new products from various parts of the world to
market, with only a modicum of concern regarding the
sustainability of their sourcing, the consistency of their
constituents, and the limited scientific background
justifying their use.  The nutraceutical companies are
looking to exploit the academic discoveries of
compounds, such as cancer chemopreventive or
cholesterol-lowering agents, which can be added to high-
volume foods, or they are seeking plants which offer new
and diverse life-style marketing opportunities (noni fruit
and acai berry are recent examples).  Investment in
research to justify the safety, use, and quality control of
these products is minimal.
With this summative background concerning the past
and present practices of natural products in the discovery
of new medicinal agents, it is opportune to consider the
appropriate role of natural products in health care systems
globally for the next twenty years.
Future Aspects of Natural Products in Drug Discovery
For future generations to thrive, be productive, and lead
meaningful lives in their respective societies, there are
two dominant factors to be considered, the health of the
planet and the health of the people.  These are not to be
separated, as we are all part of one large, fully interacting,
biological organism, Earth.  The goal must be to maintain
the health of that whole organism in a cost-effective
manner.  Failure to do so will leave a terrible legacy for
our descendants.  Consideration of all chemical
processes, including those for the synthesis of medicinal
agents, and the accessibility of drugs to those in need are
critical.  Factoring in the anticipated cost to the patient
becomes an important consideration as potential drug
candidates in any form, synthetic or natural, make the
transition from discovery to clinical development.
Already there are numerous situations where the latest
drugs are becoming (or have become) too costly for
health care systems, including insurance companies, and
their patients in the high-income world.  When it is a
Health Ministry in a country which decides which drugs
are to be imported, and at what cost, for their health care
systems, very significant compromises are typically made
in terms of access to optimal health care.  In the course of
time, these differences in access are clearly reflected in
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life-expectancy, and become another global
pharmaceutical care “gap” between the North and the
South.  At the same time, it is also recognized that
enhancing the quality of traditional medicines will have
an impact on product costs.  This is contained within the
concept of accessibility, the combination of sustainability
and affordability.
Almost lost now in the mists of time, it should be
remembered, that before 1899, when the semi-synthetic
drug aspirin, based on the natural pain reliever salicin,
was introduced, all drugs were derived from natural
sources.  Since then, a vast pharmaceutical industry, with
many companies tracing their history to the original
sellers of natural products in the latter part of the 19th
century, have evolved to develop new drugs for a myriad
of diseases. Some of the compounds introduced during
that period from 1900-2010 have been natural products,
and the more recent discovery efforts have been reviewed
by Newman and Cragg (28,29).  Most of the drugs that
have been introduced in the past 110 years are totally
synthetic.  The primary exceptions are several groups of
antibiotics, and the steroid and alkaloid derivatives which
are semi-synthetic.
It is time now to introduce the new term
“ecopharmacognosy” (38).  As we look to the future for
the practice of using synthetic medicinal agents, one
aspect of concern which requires deliberation is the
sustainability of the production of those drugs at
reasonable cost.  Both the chemicals and the chemical
reagents used in those processes are typically a non-
renewable resource, and their contemporary use depletes
the future resources for synthetic drugs.  Consequently, a
fundamental precept for all drug discovery programs, be
they synthetic or natural, must now be the concept of
sustainability (4-12,38), as an extending consideration of
the “green chemistry” movement.  One aspect of this
topic was discussed earlier in terms of the development
of alternative, renewable sources for chemical reagents
(enzyme catalysts, vegetables, etc.) (13). Selected,
valuable traditional medicines have been, or are being,
depleted in their natural environment, without alternative
resourcing being developed.  Ecopharmacognosy,
defined as the “study of sustainable, biologically active
natural resources”, must therefore become the
fundamental basis for all natural product research.
Studying plants, or any natural organism, for their use as
a global medicine, must take into account the potential
long-term sourcing.  We have already seen situations,
taxol is an example, where the drug requirements for a
clinical trial, came up against serious sourcing concerns.
Consideration of the enzymes to be used for the large
scale synthesis of drugs, must also consider the
sustainability of the resource.  Using the enzymes in
plants that are already commercial entities, such as
vegetables, assures their long-term accessibility, and
reduces cost compared with rare enzyme preparations
derived from microbial sources.  Ecopharmacognosy
therefore embraces both the development of biologically
active natural products as single agents or as components
of traditional medicines, and the resources for the
chemical synthesis of single agent drugs.  The same
considerations must also be applied as marine resources
are explored for the development of new biological
agents.
Except for some biological agents, such as vaccines,
which will not be discussed here, there are usually three
classes of single agent drugs recognized: i) totally
synthetic drugs, which are produced from non-renewable
resources, such as coal and oil; ii) semisynthetic drugs,
such as the steroid hormones which are derived from a
chiral natural product core produced in the field, or, in the
case of antibiotics, through large scale fermentation.  This
is followed by structural modification using non-
renewable resources, unless microbial transformations
are included in the synthetic strategy; and iii) natural
products, such as vincristine or morphine, which are
derived from a renewable natural resource.  In this
instance, the non-renewable aspects involve the materials
used for processing the plant material in order to isolate
the desired alkaloid.
Of perhaps thirty different aspects which could be
discussed regarding the future for natural products in drug
discovery, six will be briefly presented: i) access to the
biome, ii) acquisition and analysis of traditional
knowledge and on-going research, iii) biotechnology
development for secondary metabolites, iv) dereplication
studies, v) strategies in natural product drug discovery,
and vi) multitarget therapy and synergy research.
Access to the biome
The natural materials to be used, and any ethnomedical
knowledge not already in the public domain, are the
property of the country in which they are extant
historically.  The Convention on Biological Diversity
(CBD), approved for signature at the Earth Summit in Rio
de Janeiro in 1992, established those parameters for those
signatories who ratify the treaty.  As of April 2013, 193
countries were parties to the convention.  Only three
countries in the world had not ratified the convention:
Andorra, the Holy See, and the United States.  At the
same time, there is a natural, unresolved tension with the
TRIPS (Trade-Related Aspects of Intellectual Property
Rights) agreement of 1994 in the area of the development
of local resources by third parties.  In the TRIPS
agreement, the country of origin of the genetic material
has no sovereign rights over their biological resources or
their indigenous knowledge once there is an invention.  It
is the inventor who can claim the intellectual property
rights, with the originating source of the material,
whether it is derived from a plant, animal, or fungus in a
particular country, having no claim for compensatory
loss.  The United States was the promulgator and the first
signatory country to this Agreement.  This area, and the
whole topic of the impact of the CBD on natural products
research, has been reviewed (39), and the discussion will
not be repeated here.  Some selected aspects of the CBD
that relate to natural product drug discovery will be
mentioned briefly.
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Article 15.2 of the CBD indicates that signatory
countries should facilitate access to their biome in
exchange for present and future considerations which are
to be negotiated (39,40).  Articles 15.5 and 15.6 indicate
that all of the collections of biological material which are
made within a country should occur with prior informed
consent, and that collection of the materials should occur
with the accompaniment of local scientists.  Article 16 is
concerned primarily with issues related to access and the
transfer of technologies relevant to the conservation and
sustainable use of genetic resources under fair and
favorable terms.  Article 17 relates to the information
concerned with the conservation and sustainable use of
biological diversity and the results from scientific and
socio-economic research are promoted.  Article 18
promotes international technical and scientific
cooperation, and the development of joint ventures.
Following the CBD, there were numerous
developments related to the establishment of protocols
and systems within countries for the approval and
collection of biological materials, and the acquisition of
indigenous knowledge (39). Indigenous groups,
sometimes collaborating across national boundaries, have
also sought to establish parameters and protocols to
receive authority to provide access.  While this has had
the beneficial effect of reducing the number of scientists
from various countries taking unauthorized plant
materials or other biological resources out of a country
without local knowledge (sometimes referred to as
“biopiracy”), there has been a clear tendency towards the
over-protection of access to resources, and/or excessive
bureaucracy associated with the approval process (39).
It is this outcome of the CBD, doubtless not
anticipated by the drafters or the signatory parties, which
has led to the overall deleterious impact of the CBD on
natural products research on a global basis.  This is
because the value placed on the access to those resources
by an individual country was often too great.   The
expectation that pharmaceutical companies would line up
to seek access to areas of intense biodiversity, never
materialized.  As a result, if the approval processes, or the
restrictions, or the time and the financing required to
negotiate the associated considerations, were deemed too
onerous, academic and/or industrial laboratories declined
to invest, in either the people or the places.  Particularly,
this occurred if more amenable choices for sample
acquisition (based on bureaucracy, cost, and time), which
might well have the same plant materials, were available.
Alternatively, many pharmaceutical companies simply
chose to eliminate natural product extracts (marine,
fungal and plant) from their primary screening programs,
and, at the time, turned to other sources, such as
combinatorial chemistry, for the guaranteed expansion of
their chemical libraries.
This resulted in two scenarios.  Firstly, the
biodiversity-rich countries were unable to find
collaborations (either academic or industrial) for
programs designed to evaluate their biome for a health
care impact, and were unable to enhance the development
of much-needed taxonomic, chemical, and biological
capabilities in-country.  In some instances (e.g. the
Philippines), local scientists were also severely impacted
by strict government requirements, and their research was
essentially halted for extended periods (34).  Secondly,
local pharmaceutical development, deemed critical for
the type of initiatives being discussed to improve local
health care, was inhibited.  As a direct result, the reliance
on externally acquired pharmaceutical and medicinal
agents was maintained, benefitting the major drug
manufacturers.  Without access to biological materials,
the discovery of new biologically active natural products
is diminished and advances in health care are impeded in
that country and elsewhere.
It is important that prior negotiated agreements are
seen as an essential aspect of plant collection programs
for drug discovery, and there is a sense of pragmatism
required.  Very, very few compounds, or their
semisynthetic derivatives, will ever become a profitable
invention.  An alternative pathway is to negotiate a
graduated, two-tier approval process for the collection of
biological materials which distinguishes between the
“discovery” phase and the “development” phase.  Thus,
one agreement would cover initial collection and
academic/pre-toxicological research on limited size
samples, and the second agreement would apply only
when the acquired sample size had to be increased for
more advanced pharmacology and clinical studies.
(39,41).
On October 29, 2010, the “Nagoya Protocol on Access
to Genetic Resources and the Fair and Equitable Sharing
of Benefits Arising from Their Utilization to the
Convention on Biological Diversity” was adopted under
the auspices of the CBD (42).  It is an instrument for the
implementation of the access and benefit-sharing
provisions of the CBD, and was opened for signatures on
February 1, 2011.  It was developed after six years of
negotiation, and overall content supports and
compliments the CBD.  Only countries which have signed
and ratified the CBD are eligible to sign or ratify the
Nagoya Protocol, but a country can also have signed the
CBD and choose not to sign the Nagoya Protocol.  When
fifty countries had signed it entered into force and
countries began implementation. As of April, 2013, 92
countries had signed the Nagoya Protocol, and 16 had
ratified the Protocol (43).
The primary focus of the Protocol is on the equitable
sharing of benefits, and the requirements of signatory
nations to develop procedures for implementation and
regulation of the CBD, with a specific requirement for the
issuance of permits with respect to permission granted for
access to either genetic resources or indigenous
knowledge.  The Protocol establishes an international
Clearing House under the CBD secretariat to assist
countries with respect to developing various aspects of
the implementation process, and requires countries to
deposit appropriate records and information from their
country with the Clearing House for common availability.
Specific issues relating to trans-boundary situations must
be discussed in instances where indigenous groups
overseeing knowledge or resources are not located in a
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single country, as may occur in parts of the Andean
region, in the Middle East, and in Southeast Asia.
In response to significant criticism about bureaucratic
process and openness, ratifying countries are now
required to assure legal certainty, clarity and
transparency, both legislatively and in the
implementation of regulatory requirements, such as
applications for prior informed consent.  Countries must
also provide effective communication systems during
periods of application evaluation.  Permits which are
internationally recognized will be issued by the
recognized national authority for approved programs in a
country based on prior informed consent and mutually
agreed terms.   This information will be provided to the
newly-established CBD Access and Benefit-sharing
Clearing House.  One can imagine that the permits will
be needed both internally at various points in the process,
at the collection site, at the exportation site for genetic
material, and probably by major international journals in
the field to assure compliance with international
standards for published research articles.
Somewhat surprisingly, the contentious issues related
to patents are not discussed in the Nagoya Protocol, even
though it is an essential consideration for many groups
seeking access to genetic resources and traditional
knowledge, and an anticipated constituent aspect of any
prior negotiated agreement between parties.
Consequently, the obvious tensions with the TRIPS
Agreement remain unresolved.  Directly related to the
concerns regarding patents and the non-obviousness of
inventions is the issue of “derivatives”, which the
Protocol defines as “a naturally occurring biochemical
compound resulting from the genetic expression or
metabolism of biological or genetic resources.”  This is
not a robust definition of a derivative, and it is easy to
imagine how a corporate entity could develop derivatives,
be in accordance with mandates of the Nagoya Protocol,
and still be the sole recipient of patent rights.  Another
significant omission from the Nagoya Protocol is the
absence of mandatory checkpoints or benchmarks which
a certificate holder should be required to reach during the
application and experimental processes.  Individual
countries are however, permitted to include benchmarks
of performance and reporting as they deem necessary.
Acquisition and analysis of traditional knowledge and
on-going research
It has been said that the countries which will be successful
in science and technology in the future will be those who
use the globally available knowledge most creatively to
generate new knowledge and inventions.  This “smart”
technology is desperately needed as strategies and
considerations for the exploration of the tropical forest
are initiated. Information, ethnomedical, botanical,
chemical, and biological, is burgeoning. New
technologies which may impact drug discovery programs
are being developed at an incredible pace.  Almost every
country, and within them most scientific research
laboratories, when they are connected to the internet,
have essentially unlimited access to this information,
most frequently at no or minimal cost.
With respect to traditional knowledge, the ease of
access to information has its benefits and hazards.  The
benefit is that more information on the use of a plant can
be compared than merely relying on one or two local
compendia of information.  The hazard is whether all of
the available information has been acquired legally under
local regulations, particularly knowledge of the use of
indigenous plants acquired since the CBD.  Another
consideration is that the vast amount of published
ethnomedical information, collected by ethnobotanists
and medical anthropologists, on the use of plants for
medicinal purposes, is extremely scattered, and is
therefore very difficult to acquire in toto.  Undoubtedly,
there is always more literature to be unearthed on the use
of a particular plant, if only the resources were available.
As stated on several occasions (3,4,6-12), there is a
dire and urgent need for an international agency, possibly
in collaboration with a global foundation, to fund the
development of a central repository of indigenous
knowledge, a sort of “WikiEthnoMed” .  But the data base
repository should not end there.  As well as ethnomedical
information, data on the biological evaluation of plant
extracts and their constituents, the chemistry of the
natural plant sources, and the clinical evaluation of plant
extracts, needs to be acquired and collated.  Data on the
safety and possible or observed adverse events associated
with traditional medicines are also required to be collated
for open access, as a health care consideration for
practitioners and patients.  At this stage in the 21st
century, it should be possible, where ever one is in the
world, to indicate a plant name and then find its barcode
(vide infra), ethnomedical information, chemical
constituents, biological activities, and clinical evaluation
data.  It is estimated that such an on-line, global health
resource, once established, and depending on physical
location(s), would cost about $5 to 7 million to operate
each year; a veritable bargain given the health care
benefits.
For the development of rational, sustainable drug
discovery from plant sources the first step is a critical
evaluation of all of the available information on a plant,
or on the plants to be evaluated for a particular health
benefit, such as antihyperglycemic activity.    This is
needed in order to prioritize plant acquisition plans, avoid
the unnecessary duplication of research effort, and
optimize the consumption of precious (financial,
personnel, and oil-based) resources.  There are also
important ecopharmacognosy considerations of
sustainability which enter into these strategies as well.
Biotechnology development for secondary metabolites
When one acquires, dries, and then extracts a plant
material, the observed chemical profile is the
phytochemical equivalent of a “Kodak moment” (10-12).
For over 180 years, phytochemistry, and by inference
chemotaxonomy, tacitly accepted that this “moment”
represented the biosynthetic capacity of that plant.  Now
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it is well-established, through the use of tissue culture,
cell-free systems, and elicitor molecules such as methyl
jasmonate, that this is an inappropriate paradigm, and
represents only a partial view of genetic capacity for
secondary metabolite formation.  Indeed, it is more like a
“still shot” from the dynamic secondary metabolite
profile “movie” of the plant.  For no single plant on Earth
has the full metabolic profile yet been determined through
analysis of the genes of secondary metabolism and then
demonstrated through expression.  A more complete
understanding of what a plant is in terms of a chemical
factory for making secondary metabolites of biological or
clinical interest, may be very important to achieve on a
selective basis in the future.
Thus, a single extract of a plant, taken at a single point
in time, cannot reflect the constituent range of that plant,
ignoring as it does numerous intrinsic and extrinsic
factors, including dormant biosynthetic genes which will
alter the chemical profile, and thus the biological
outcome.  The ability to modulate these genes, and thus
the enzymes they code for, in a controllable manner, will
be a critical aspect to enhancing plant secondary
metabolic diversity for biological screening, and in
establishing reproducible production levels for needed
metabolites, especially for the constituents of traditional
medicines.
Fungal genetics has progressed remarkably from the
perspective of understanding secondary metabolic
profiles and production in recent years, and inferences
with respect to the evolutionary aspects of fungal
organisms are developing rapidly (44).  Because of
challenges with the locations of metabolic genes, plant
genetics has lagged somewhat.  However, as these details
of the plant genes responsible for secondary metabolite
biosynthesis are recognized, it becomes possible to
express the genes in other, faster-growing formats (E.
coli, yeast, insect cultures, etc.), and produce either a new
range of metabolites previously unknown from that plant,
or a desired enzyme, compound or series of compounds
with a significantly higher degree of control (45,46).
From a biological screening perspective, it will be
important to identify the regulatory genes responsible for
secondary metabolite production control, and thereby
modulate the secondary metabolite profile, so that rather
than being a snapshot, it can indeed become a movie.
Both the short and long-term implications of this are
clear.  Maintaining the genetic capacity of the tropical
forests, which has taken billions of years to evolve,
through conservation, acquisition and botanic garden
development, or sampling and storing germplasm, is a
critical aspect of a diversified and well-considered long-
term medicinal agent discovery program for a nation.  It
may be that locked in the DNA of a plant are the genes to
produce crucial drugs in the future, once it is possible to
more completely understand the contortions of their
metabolic formation.  Certainly, it is unconscionable to
destroy the forests without first sampling and preserving
the breadth and depth of the diversity of genetic resources
that are within.
There are numerous other aspects of biotechnology
which impinge on natural product drug discovery and
development, including bioassay design and
implementation, drug delivery systems, and enhancement
of natural product structural diversity (vide infra).  Some
aspects of these technologies have been discussed
elsewhere (5-7,9-12).
Dereplication studies
Plants are chemical factories which produce a wide range
of metabolites of various structural types.  Many plants
across taxonomic borders have evolved the genes to
produce similar or identical metabolites.  The wide spread
occurrence of common flavonoids, such as quercetin and
related derivatives, is an example.  Once an extract is
declared “active”, prioritization along with other “active”
extracts for bioactivity-directed fractionation is needed.
Frequently, there are more active plants than capacity
(human) to fractionate.   At this point, there are three
research options: i) eventually fractionate all the extracts;
ii) introduce a secondary bioassay to discern a more
selective priority list, or iii) apply a dereplication strategy.
Dereplication is a process to delineate, in an active
extract, the probability that the active principle is likely
to be novel.  Such a determination can re-prioritize active
extracts, and/or eliminate extracts for further
examination, and it can improve the efficiency of
isolating the active principle.  Several years ago we
described an HPLC/ESMS/bioassay/database
dereplication system for active natural products in
biologically active matrices (47), and went on to describe
how it was used on active extracts for the identification
of both new and known natural products (48).
Refinements in dereplication systems include: i)
development of software which can rapidly correlate
mass and biological data to a chemical and biological
database so that searches and conclusions can be achieved
on-line, ii) introduction of continuous flow NMR to
support postulated structures of active masses, and iii)
recognition of carbon-13 NMR to provide an even higher
level of certainty regarding the possible skeletal structure
and functional group disposition of a molecule within the
matrix.  Over time, the ability to characterize the majority
of the known major active constituents in an extract
without isolation will become a standard practice.  A
further use for such HPLC/ESMS/NMR/bioassay system
technology, other than drug discovery, will be for the
chemical and biological standardization, as well as
metabolomic studies of traditional medicine samples, on
a batch to batch basis, once the appropriate active
principle(s) have been identified.
Strategies in Natural Product Drug Discovery
It is an important question to ask whether natural products
are drug molecules.  Several years ago (21), it was shown
that those alkaloids which are presently available as
pharmaceutical agents are a good fit (with some outlying
molecules) to Lipinski’s “rule of five”.  When an analysis
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of 120,000 compounds in the Dictionary of Natural
Products was conducted, 65% had no violations of these
rules, and this led to the development of a natural product
library of over 500 compounds for drug screening (49).
Other studies have supported these conclusions (50,51).
Thus existing natural products can form the basis of a
drug discovery program complementing the development
of potential new sources of bioactive molecules.
Strategic considerations for the development of
natural product drug discovery programs abound
(17,19,52-54).  How the plants will be collected (random,
phytochemical, ethnomedical), how plants will be
extracted (water, non-polar, and polar solvents), which
biological assay to use (animal, whole cell, organ tissue,
enzyme, receptor), and how to establish levels for
“activity” are strategic decisions which must be taken
prior to initiating the program and then reviewed
regularly during the program.
It is also important to recognize that a plant is not a
single organism.  There are numerous fungi, bacteria,
and, in some cases, algae, symbiotically associated with
the plant.  These organisms are also biosynthetic
factories, and the study of pathogenic and parasitic
organisms may offer the potential to enhance the range of
natural product structures in a sustainable, albeit rather
unpredictable, manner.
Accessibility to resources, reproducibility of activity
in recollections, and the time to yield an active isolate are
important concerns in the involvement of plant extracts in
drug discovery (1-3,10-12).  There are several other
issues which can also affect the overall discovery process.
We have seen that isolation of known compounds with a
known bioactivity is a significant issue in some biological
areas (such as cancer), and there is also the patent concern
of known compounds which may afford new biological
activities.  Patenting inventions has become an important,
though not essential (vincristine, taxol, and camptothecin
were never patented), function for both industrial and
academic discovery programs, and the strongest drug
patents are those which claim a new chemical entity with
a new biological activity.
Sample repositories are an essential aspect of any
plant-based drug discovery programs.  Typically, as a
program evolves, there are three types of repository that
are needed: i) for the plants acquired, ii) for the extracts
made, and iii) for the compounds isolated.  The first may,
in part, be the local, internationally recognized,
herbarium where a formal, classically prepared specimen
is stored for posterity.  Also needed is a dry, air-
conditioned, moderate temperature (0-10˚C) facility for
storing the remainder of collected, but unused samples,
appropriately labeled and catalogued in a database. The
second repository is for residual samples of all extracts
and fractions that are prepared, usually held at -20ºC or
below, and again systematically catalogued electronically
and organized in individual, barcoded vials for easy
access.  Frequently, sample specimens of extracts are also
stored in 96-well plates for screening purposes,
depending on strategic demands based on the available
and projected biological assays.  Finally, purified and
isolated compounds must be catalogued and stored, both
in vials, and in 96-well plates for further screening.  Long
term, the drug discovery goal should be to screen every
isolate against every relevant bioassay.  Electronic
cataloguing and analysis of this information is important,
as is recognizing that data base access should be available
to all collaborators.  Of course a fourth database, not
experimental in nature based on the current studies,
should constitute an inventory of information on the
previously reported studies on all of the plants actively
under study.  The first step in deciding whether to actively
work on a “hit” extract is to become fully aware of all of
the prior literature on that plant and related species.  It is
another example of “information first” as a philosophical
precept.
Identification of the plant materials to be used for
discovery purposes is very important as a basis for the
whole program.  But how is the plant to be identified?
Preliminary identification may come from morphological
examination and herbarium specimen comparison.  For
several years, DNA techniques, such as random amplified
polymorphic DNA (RAPD), amplified fragment length
polymorphism (AFLP), and inter-simple sequence repeat
(ISSR) analysis were deployed as an adjunct for plant
identification, and for studying the genetic variation in
medicinal plants (55).  Now the focus is on the
development and application of DNA barcoding (56), as
one facet of the Consortium for the Barcoding of Life
(CBOL), and some background details pertaining to
medicinal plant identification have been discussed (9-12).
The DNA fragments which are considered appropriate to
use for species identification at this time are focused on
the ITS2, matK, and trnH-pasbA genes.  Reliability rates,
the ability to make positive medicinal plant identification
based on specific genes at the genus and species level, are
typically very high (76-96%).  Chen and co-workers (57),
using seven DNA barcodes (psbA-trnH, matK, rbcL,
rpoC1, ycf5, ITS2 and ITS), studied over 6600 plant
samples from 753 genera and 4800 species.  They found
that the ITS2 barcode gave a 92.7% successful
identification rate, and thus could potentially used for the
identification of medicinal plants.  How this relates to
secondary metabolite production, and therefore to a
reproducible biological activity, remains an area for
future exploration.  Another significant future
development is the incorporation of barcoding
technology into highly automated, hand-held devices
which could provide extremely rapid, in-field
identification of plants (58).
Principal component analysis (PCA) of the low
molecular weight (ca. 200-500 daltons) compounds in a
plant as a part of metabolomic studies is also changing
how a plant is defined (59).  It will become an important
component of drug discovery programs to assure
adequate compound sourcing in recollected materials,
either for expanded biological evaluation or possibly to
meet production demands.  The combination of these
techniques means that the identification of plants through
gross morphology or macroscopic examination is rapidly
being supplanted.
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The gene-based and chemical analysis techniques now
demonstrate that within a recognized plant “species”
there are many “forms”, “races”, or “chemotypes”.  These
plants will have different functional genetic profiles
under different circumstances, different biosynthetic
capacities based on those gene profiles, and therefore
variable and complex chemical matrices.  This begins to
explain why reproducible plant recollection is so
challenging and frustrating.  Within the next few years,
DNA barcoding, and probably PCA, will become
essential and integral aspects of all medicinal plant
identification, whether for drug discovery programs, or
for standardization of traditional medicines and
phytotherapeuticals.  The result may be that the concept
of a Latin binomial name for a plant, romantic though that
is, will be replaced, or added to, by a series of identifiers
which will define both the integrity and the quality of the
sample.
In the biological evaluation of plant extracts tannins
are a frequent confounding factor and must be removed
when either enzyme or receptor-based assays are
involved (60).  This has led to the development of
detannification and partial fractionation techniques to
form peak libraries of dominant compounds in an extract
which can then be screened.  While minor bioactive
compounds may be missed, this strategy does begin to
address the issue of adequate subsequent supply when
bioactivity is found, a core consideration of
ecopharmacognosy (38).
Various data mining strategies may also be used to
construct libraries of plant extracts or individual
compounds, once adequate, pre-existing literature has
been compiled.  Chemical space matches and
pharmacophoric models also provide an in silico
approach to the identification of compounds of potential
interest which can then be isolated or further derivatives
sought.  Rapid access to plant materials as potential
resources, based on existing isolation or chemotaxonomic
information to identify plants for collection, is then an
essential component of the discovery strategy.
Multitarget Therapy and Synergy
In considering both the quality control and the drug
discovery perspectives of traditional medicines, two
aspects are significantly undervalued in terms of
therapeutic outcome, multitarget therapy and synergy.
Rather than the classical “magic bullet” approach,
therapeutic outcomes have improved significantly for two
of the most important disease states, cancer and AIDS, as
a result of strategically assembled multicomponent
regimens derived from considering a diverse mechanistic
targeting system (61).  Ethnomedicine has already
established that model of therapy.  The chemical factory
of a plant, and even a hot water extract, will contain a
multitude of constituents, and multicomponent plant
regimens, in which five, ten, or even twenty plants are
used in a prescription, provide an unprecedented range of
highly diverse chemical constituents which are affecting
multiple sites and acting by diverse mechanistic
pathways.  An important question is whether there is clear
evidence of rational use for the role of each individual
component plant in a multicomponent traditional
medicine? As evidence-based traditional medicines are
explored for drug discovery and validation this will
become an important experimental target, and eventually
a consideration in the sustainability of that product.  A
recent discussion on network pharmacology provides an
important framework for these deliberations, and for the
potential design and discovery of new agents with
unsuspected biological activity (62).
The biological effects observed in vivo or clinically in
an extract may be due to one or more active compounds
acting at different sites.  Alternatively, two, or more,
components in the mixture could be acting in a synergistic
or in an antagonistic manner.  In addition, the effects
when a traditional medicine is taken with a single agent
drug are unknown, resulting in a possible adverse drug
reaction (ADR) which may potentiate or inhibit the
actions of the single agent drug.  When combinations of
medicinal plants are used, as in many drug systems
around the world, the situation becomes significantly
more complex.  Williamson (63) and Wagner (64,65)
have stimulated discussion in this area.
A significant issue in studying synergy and
antagonism in multicomponent traditional medicines has
been technique and definition (65).  Berenbaum (66) used
a mathematical definition based on an isobole to represent
these biological outcomes, so that the effects of a
combination of agents are independent of the mechanism
of action, and can be presented graphically.  A powerful
demonstration of a synergistic interaction between two
natural products occurs with mixtures of ginkgolides A
and B examining platelet aggregation (67).  Potentiation
of the effects of kava-kava and a Passiflora extract as a
sedative, and of a complex preparation of nine plants for
dyspepsia whose constituent plants demonstrate effects
on a range of motility-related disorders have also shown
synergistic results (64,65).  The protocols developed for
these studies may have an important influence on the
evolving strategies for the evaluation of the quality,
safety, and effectiveness of an individual traditional
medicine, and on the discovery and development of new,
more effective combinations of medicinal plants
(“designer traditional medicines”). In addition, they may
offer strategies to increase the sustainability of particular
medicinal plants, if the synergistic effects can be
quantified and reliably reproduced.  Critically, such
experiments require that the extract is well standardized
and the biological mechanisms are well clarified prior to
synergy experiments being initiated.
Challenges and Strategies for the Future
A vision for natural products derived from the tropical
forest is based on the concept that sustainable
considerations and strategic thinking are needed now.  In
addition, those resources will be needed even more in the
future, in order to provide medicinal agents as fossil
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based resources become depleted during a period when
the global population is increasing rapidly.  Such a vision
involves the creation of a new term, ecopharmacognosy,
to describe the philosophical shift, and requires new
paradigms for the conduct of the natural product sciences
on a global basis, including new balances of program
development for drug discovery and traditional medicine
quality control, new strategies, a new emphasis on
evidence-based research, new alliances between various
collaborators in academia, industry and government, and
new values for what is meaningful, natural product
research for health care enhancement (8-12,38).
It should be readily apparent that humankind cannot
survive another century as destructive of the Earths’
resources as the 20th century.  Twenty-one years after the
Rio Summit of 1992 we are as “irresponsible” as ever
with respect to our biodiversity.  At the end of the last
century one-eighth of all plant species were threatened,
50% of bird species are likely to become extinct by 2050,
and affordable oil resources are estimated to last until
2060.  The abiding concern which the world must grapple
with now is whether, as a human race, we can see these
issues as being our destruction and own our responsibility
in any attempted restoration of a balance within Gaia (1).
It is critical that we are mindful of the balance between
the conservation of the existing rain forests, and the
destruction of these fragile and deeply interwoven
ecosystems and their deforestation for crop and grazing
lands.  Our concerns are for ecological, climactic, and
geological reasons, and as a way to maintain the bio-, and
therefore chemo-, diversity within those forests.  As
described within ecopharmacognosy, plans for the
development of new medicinal plants in any form to fill a
market niche must be sustainable.  An appropriate
balance is needed between intellectual property rights and
the burgeoning technology of drug discovery.  A balance
is also needed between all those who are stake holders for
biodiversity and indigenous knowledge and those who
have the capacity to potentiate (create value) in that
biodiversity for health and economic benefit.  This is the
balance that is needed between the CBD/Nagoya
protocols and the TRIPS agreement (39).
Numerous new alliances, both internal and external
will be needed to effect the rational development of
tropical forests for new medicinal and biological agents.
Some may already be in place; they need to be
strengthened.  Other alliances will be new; they will need
to be carefully nurtured.  Diversity of expertise and
experience indicates that the alliances will be both local
and global in nature.  They will involve individuals and
groups who have the capacity for high level collaboration
and low level ego involvement.  Several examples of such
collaborative programs have been described (1,52-54).
The strongest programs, rather than being solely based in
academia, will have industrial and government partners
working together for a common goal, enhanced health
care for the patient.  Countries which are engaged in
medicinal agent discovery programs based on local
natural resources are recommended to examine the
structure and functioning of these programs as a potential
model for collaborative investment to promote the
development of local medicinal plants and natural
products.  In a sound and comprehensive health care
program, such alliances are an integral aspect (6-12,38).
In order to accomplish these goals though we must create
value; value in places, in people, and in plants.
The tropical forest is a huge vast ecosystem which is
comprised mostly of “weeds”, those “plants whose
virtues have yet to be discovered”, as Ralph Waldo
Emerson suggested in the late 19th century.  An important
responsibility for natural product scientists to the
generations following is either to demonstrate the value
of biodiversity through new discoveries of plant-derived
medicinal agents, or to leave the resource alone and
protected.  Solid linkages which unite the interests of
environmental preservation, medicinal plant research and
drug discovery, and the development of the agro-
industrial enterprise are therefore crucial.  Examining
import levels of finished pharmaceuticals and natural
products (essential oils, and flavor and fragrance
materials) in the context of developing local industrial
capacity is important.  Structured and well-monitored
natural product development programs based on tropical
forest resources could lead to reduced imports and
increased exports.
A vision of the natural product sciences contributing
to global health care offers very significant challenges to
many countries.  A primary challenge is to catalog and
preserve the bio- and chemo-diversity of the rainforests
(and the oceans) for the benefit of future generations.  A
secondary challenge is the need to catalog the eco- and
ethno-information on plants, and the chemistry and
biology of their products, so that the information can be
collated, analyzed, and accessed globally in real time.
Exploration aimed at potentiation of the biota of the
world from any of several aspects, including drug
discovery, necessitates systems being available locally
which can offer equitable access to the biome and
substantial assurances with respect to intellectual
property rights and investment commitments.  Many
medicinal plants, some of them threatened or endangered,
are presently in commerce in various parts of the world,
either for the production of single agent drugs, or in
traditional medicine preparations. Medicinal plant
germplasm banks in selected locations throughout the
world are needed to preserve these crucial resources, in
the same way that seed crop banks are used for important
food crops.  At the same time, contemporary techniques
for plant identification, including DNA barcoding, must
become integral aspects of what is considered plant
identification, whether these plants are being investigated
or used as medicinal plants, or whether they are being
pursued for possible drug discovery of standardized
preparations or single agents.
The sustainable development of plants and their
extracts or fractions which are marketed for health care
purposes is critical.  A “Sustainability Index” probably
needs to be developed, so that patients can clearly see
from a label how the product was harvested and prepared.
A product derived directly from the forest and extracted
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in a manner where an organic solvent was not fully
recycled would get a rating of “0”, whereas one harvested
organically in a sustainable manner with full recycling of
any solvents, might get a rating of “5”.  Individual
compounds and plant extracts must be evaluated using
contemporary procedures and targets for both quality
control and drug discovery.  Strategies should be
developed for genomics-based, in-field bioassays to
evaluate plant extracts in the field, to avoid bringing dried
(or fresh) plant materials to the laboratory for extraction
and bioassay.  The number of natural products presented
to test systems for biological evaluation could be
enhanced through chemistry, combinatorial synthesis,
combinatorial biosynthesis, and other strategies.  Drug
discovery programs must be introduced, strategically
developed, and enhanced based on local plants and for
local diseases.  Most importantly, integrated global
alliances are needed both in-country, and between
developed and developing countries, for medicinal plant
product development, in order to optimize the utilization
of facilities, infrastructure, and personnel who are needed
to conduct the above programs.
How can these goals and the associated programs be
initiated?  First of all it must be said that plans of the scale
described in this article and elsewhere (4-12,38) begin
with small scale initiatives, reasonable benchmarks, and
an appropriate timetable.  They are not instantaneous
“fixes” of the situation, nor will they yield rapid results.
Strategic planning at the highest levels is required,
combining government agencies, industrial enterprises,
international agencies and foundations, academic
institutions, and private consultants with natural product
drug discovery and development experience.  Planning
and proposal development may take 1-2 years of
meetings, discussions, and consultations to evolve.  Over
time, countries, or consortia of countries, will require an
infrastructure to foster the development of their own
sustainable medicinal agents from natural sources based
on the quality of their natural product sciences.  Programs
will be needed to assist countries to potentiate their
infrastructure and resources, including their facilities and
their scientists, in order to evaluate and standardize
natural product-based medicinal agents on a sustainable
basis for their health care systems, and that may take 5-
10 years to evolve.
Ideally, as proposed originally in 2002 (3), what is
drastically needed is a Global Alliance for Natural
Product Development and Health Care.  Such an alliance
would be composed of international agencies (WHO,
UNIDO, UNDP, NATO, EU, WIPO, etc.), government
agencies (NIH, NSF, NIE, SRC, DAAD, etc.), global and
local pharmaceutical companies, academic institutions,
non-government organizations (WWF, WRI, CYTED,
TRAMIL, IFS, TWAS, etc.), scientific societies (IUPAC,
RSC, ASP, PSE, GA, JSPS, etc.), and major foundations
(Ford, Gates, MacArthur, Rockefeller, Nippon, etc.).  A
mechanism to bring representatives together to discuss
the global issues and implications in new terms, with a
new set of goals, with a new agenda, but most importantly
with a new vigor, is vital for the global development of
natural product based drugs for health care.
Conclusion
Globally, natural products, in the form of purified active
principles and plant extracts, are the cornerstone of
primary health and for the amelioration of life-style
conditions, and will remain so for decades to come.  With
a burgeoning population, the challenges for health care in
the future remain significant.  For most of the major killer
and chronic diseases in the world there are no truly
effective drug treatments. Drug resistance to existing
chemotherapeutic regimens for fungal and bacterial
infections, for AIDS, for cancer, and for malaria, is
increasing in an unabated and alarming manner.  Many
killer and debilitating diseases in the middle and low-
income areas of the world exist without any effective drug
treatment, or even a drug discovery program, in place.
Yet, overall health care is slowly improving, life
expectancy is rising in most countries, and more children
are surviving beyond their first five years. These are
contributing factors to the dramatic rise in the global
population.  However, without a new strategic approach,
this population will not have adequate resources to
provide basic health care.  There is no choice in this
matter, medicinal plants must be an essential, sustainable,
and fully integrated element in any global health care
strategy.
Essential components of a strategic plan for
potentiating the rain forest for health purposes include:
enhancing the natural product plant sciences on an
international basis, developing multi-centered research
partnerships embracing the chemical and biological
sciences, and expanding facilities and training programs
which focus on the technologies for developing local
natural products for health care, and protecting global
resources.  This paper, like its several predecessors (1-
12,38), is another clarion call to critical decision-making
and action by governments, international agencies, and
pharmaceutical companies to commit to the sustainable
development of natural products as necessary medicinal
agents for an unprecedented level of human habitation of
Earth.
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